Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
July 17 2024 - 8:30AM
Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”),
an agricultural bioscience company, today announced that the
Company has signed a Memorandum of Understanding (“MOU”) and
License Agreement with Nuseed Nutritional US Inc. (the seed
technologies platform of Nufarm Limited (ASX:NUF)), granting Nufarm
a commercial license to certain Omega-3 intellectual property
assets, materials and know-how for producing oil in Camelina. Under
the License Agreement, Nufarm will pay Yield10 up to USD $5
million. Nufarm and Yield10 have additionally agreed to immediately
negotiate exclusively with each other for the sale of Yield10’s
remaining assets to Nufarm. The asset sale will require an
affirmative vote from the shareholders of Yield10, and a special
meeting of shareholders will be convened to seek that vote
following execution of the asset purchase agreement.
Producing omega-3 fatty acids in Camelina may represent a way to
enable a predictable, land-based supply of high-quality omega-3
oils to meet the growing global demand for eicosatetraenoic acid
(“EPA”) and docosahexaenoic acid (“DHA”). Currently, the primary
source of EPA and DHA remains ocean-caught fish, where omega-3 oil
produced from anchovy harvest is the industry benchmark. Over the
last few years, there has been increasing pressure on the supply of
omega-3 oil due to over-fishing.
“Yield10 camelina assets and know-how in both omega 3 and
bioenergy sectors have a unique fit with Nufarm’s Value Beyond
Yield® and platform strategies,” said Greg Hunt, CEO and Group
Executive of Nufarm. “While the program still requires further
development time and investment before achieving revenue, it offers
a broadened portfolio of solutions for our customers both at the
farm-gate and with end-use customers.”
“We believe that the transition of our Omega-3 Camelina program
to Nufarm is in the best interest of our shareholders, business
partners, and employees,” said Oliver Peoples, Ph.D., President and
Chief Executive Officer of Yield10 Bioscience. “We believe that the
initial payment will allow us to manage key biological assets and
regulatory requirements while providing us with the cash runway to
secure the shareholder vote. We anticipate
collaborating closely with the Nufarm team to finalize the asset
purchase agreement and complete the shareholder vote. We believe
that this will ensure a smooth transition and enable Nufarm to
expedite the commercialization of plant-based omega-3 oils produced
using Camelina."
About Nufarm
Nufarm is a global agricultural innovator providing crop
protection and seed technology solutions to help our customers grow
a better tomorrow. Established over 100 years ago, Nufarm is listed
on the Australian Securities Exchange (ASX:NUF) with its head
office in Melbourne, Australia. Nufarm is the first company to
develop and commercialise plant-based omega-3 and has developed and
commercialized advanced bioenergy feedstock technology. Learn more
at: nufarm.com.au.
About Yield10 Bioscience
Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an
agricultural bioscience company that is leveraging advanced
genetics to develop the oilseed Camelina sativa ("Camelina") as a
platform crop for large-scale production of sustainable seed
products. These seed products include feedstock oils for renewable
diesel and sustainable aviation biofuels and omega-3 (EPA and
DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed
applications. Yield10 is headquartered in Woburn, MA and has a
Canadian subsidiary, Yield10 Oilseeds Inc., located in Saskatoon,
Canada.
For more information about the Company, please visit
www.yield10bio.com, or follow the Company on X (formerly
Twitter), Facebook and LinkedIn.
(YTEN-G)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements, which
are made pursuant to the safe harbor provisions of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, the successful completion of the asset purchase
agreement by Yield10 and Nufarm, including an affirmative vote by
the Nufarm board of directors and Yield10 shareholders, the
potential future commercialization, potential market opportunity,
economic viability and further development of the omega-3 varieties
of Camelina and the omega-3 oils produced therefrom, and the
potential for the omega-3 production technology to provide
sustainable alternatives to existing means of omega-3 oil
production, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including, but not limited to, the
Company’s ability to secure adequate funding in the near term to
continue operations, as to which no assurance can be given, as well
as the risks and uncertainties detailed in Yield10 Bioscience's
filings with the Securities and Exchange Commission. Yield10
assumes no obligation to update any forward-looking information
contained in this press release or with respect to the matters
described herein.
SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND
OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY YIELD10
BIOSCIENCE FOR USE AT ITS SPECIAL MEETING WHEN AND IF THEY BECOME
AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION,
INCLUDING INFORMATION RELATING TO THE PARTICIPANTS IN ANY SUCH
PROXY SOLICITATION. WHEN AND IF COMPLETED, A DEFINITIVE PROXY
STATEMENT AND A FORM OF PROXY WILL BE MAILED TO STOCKHOLDERS OF
YIELD10 BIOSCIENCE AND WILL BE AVAILABLE AT NO CHARGE AT THE
SECURITIES AND EXCHANGE COMMISSION’S WEBSITE AT HTTP://WWW.SEC.GOV.
INFORMATION RELATING TO THE PARTICIPANTS IN THE PROXY SOLICITATION
WILL BE CONTAINED THEREIN.
Contacts:
Nufarm:Corporate/Media: Rhonda Macdonald, (403)
660-9717, rhonda.macdonald@nuseed.comInvestors: Grant Saligari, +61
406 402 645, grant.saligari@nufarm.com
Yield10 BioscienceLynne H. Brum, (617)
682-4693, LBrum@yield10bio.com
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Oct 2024 to Nov 2024
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Nov 2023 to Nov 2024